Publications by authors named "J Lauriello"
Glutamatergic dysfunction is implicated in schizophrenia pathoaetiology, but this may vary in extent between patients. It is unclear whether inter-individual variability in glutamate is greater in schizophrenia than the general population. We conducted meta-analyses to assess (1) variability of glutamate measures in patients relative to controls (log coefficient of variation ratio: CVR); (2) standardised mean differences (SMD) using Hedges g; (3) modal distribution of individual-level glutamate data (Hartigan's unimodality dip test).
View Article and Find Full Text PDFIntroduction: The clinical course of schizophrenia is often characterized by recurrent relapses. Blood inflammatory markers are altered in acute psychosis, and may be state markers for illness relapse in schizophrenia. Few studies have investigated longitudinal, intra-individual changes in inflammatory markers as a predictor of relapse.
View Article and Find Full Text PDFDetermine if sublingual dexmedetomidine, a selective α adrenergic receptor agonist, reduces symptoms of acute agitation associated with schizophrenia or schizoaffective disorder. This phase 3, randomized, double-blind, placebo-controlled study was conducted in adults diagnosed with schizophrenia or schizoaffective disorder per the , Fifth Edition () criteria. The study was conducted at 15 US sites between January 23, 2020, and May 8, 2020.
View Article and Find Full Text PDFArticle Synopsis
- Continuous antipsychotic therapy is crucial for managing schizophrenia, and long-acting injectable (LAI) medications like aripiprazole lauroxil (AL), approved in 2015, help minimize treatment gaps that can lead to relapse.
- A study using Medicaid claims data found that among 485 patients starting AL, inpatient admissions dropped by 22.4% and overall inpatient costs decreased by an average of $2836 within six months after starting the medication.
- Although outpatient pharmacy costs increased, the overall costs remained similar pre- and post-AL initiation, with patients previously on oral antipsychotics showing particularly significant improvements in inpatient and emergency room visits.
Importance: Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear.
Objective: To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites.